The patent will provide Eurand with coverage until at least 20 February 2028 on ZENPEP® (pancrelipase) Delayed-Release Capsules.

In 2009, the U.S. Food and Drug Administration (FDA) granted ZENPEP five years of marketing exclusivity as a New Chemical Entity.

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Its technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles and taste-masking orally disintegrating tablet (ODT) formulations.